Comprehensive Outcomes for After Cancer Health

  • Recruiting
  • Supportive care
  • Interventional
  • Randomized
  • Behavioral & Device
  • Pack Health
  • 18 Years -


Study Purpose

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.

Intervention

Behavioral : Digital Health Coaching Program

Device : Fitbit


Eligibility Requirements

info icon Have primary diagnosis of cancer;

info icon Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer 1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy 2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment).

info icon Are aged 18 years and older;

info icon Can read and consent to participate in the trial;

info icon Can read and speak English;

info icon Can complete study follow-up at pre-specified intervals;

info icon Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.

info icon Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;

info icon Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)

info icon Have a life expectancy of \<6 months, and/or

info icon Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.

info icon Healthy Volunteers must:

info icon Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.

info icon Must reside in the same dwelling as the patient participant

info icon Can read and consent to participate in the trial;

info icon Can read and speak English;

info icon Can complete study follow-up at pre-specified intervals;

Recruiting status

Recruiting

Estimated enrollment

625

 
Study start date

Jun 23, 2022

Study end date

May 31, 2027

Last updated

Mar 24, 2025

Primary purpose

Supportive care

Design

Interventional

Intervention

Behavioral & Device

Study phase

NA

Allocation

Randomized

 

Sponsor:

Pack Health

Collaborator:

Daiichi Sankyo

GlaxoSmithKline

University of Nebraska

Ohio State University Comprehensive Cancer Center

The University of Texas Health Science Center, Houston

M.D. Anderson Cancer Center

University of Florida

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Gilead Sciences

National Institute of Nursing Research (NINR)

Investigator:

Marilyn Hammer, PhD

Alexi Wright, MD

Elizabeth Arthur, PhD

Jessica Krok-Schoen, PhD

Robin Lally, PhD

Rachael Schmidt, DNP

Debra E Lyon, PhD

Anneliese Gonzalez, MD

Kathrin Milbury, PhD

Kristen Fessele, PhD

NCT05349227

Clinic Location Investigator Distance RECRUITING STATUS Contact